Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer by Liu, Yunhua et al.
ARTICLE
Targeting 17q23 amplicon to overcome the
resistance to anti-HER2 therapy in HER2+
breast cancer
Yunhua Liu 1,2,3, Jiangsheng Xu4,5, Hyun Ho Choi2, Cecil Han2, Yuanzhang Fang1,2, Yujing Li1,2,
Kevin Van der Jeught 1,2, Hanchen Xu1,2, Lu Zhang1,2,3, Michael Frieden1, Lifei Wang1, Haniyeh Eyvani1,
Yifan Sun1, Gang Zhao 6, Yuntian Zhang4,5, Sheng Liu1, Jun Wan1, Cheng Huang7, Guang Ji 3,
Xiongbin Lu1,2,8, Xiaoming He 4,5,9,10 & Xinna Zhang1,8,11,12
Chromosome 17q23 ampliﬁcation occurs in ~11% of human breast cancers. Enriched in
HER2+ breast cancers, the 17q23 ampliﬁcation is signiﬁcantly correlated with poor clinical
outcomes. In addition to the previously identiﬁed oncogene WIP1, we uncover an oncogenic
microRNA gene, MIR21, in a majority of the WIP1-containing 17q23 amplicons. The 17q23
ampliﬁcation results in aberrant expression of WIP1 and miR-21, which not only promotes
breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1
and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the
HER2+ breast cancer cells harboring 17q23 ampliﬁcation. To overcome the resistance of
trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for speciﬁc co-
delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound
reduction of tumor growth. These results demonstrate the great potential of the combined
treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast
cancers.
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Genomic studies have identiﬁed distinct breast cancersubtypes with differences in survival and response totherapy, including luminal A, luminal B, basal-like,
HER2+ and Claudin-low subtypes1,2. HER2 overexpression leads
to aggressive cancer phenotype and poor patient survival.
Trastuzumab, a humanized HER2 antibody, shows considerable
clinical efﬁcacy and extends the overall survival of patients with
HER2+ breast cancer. However, the overall response rate to
trastuzumab-containing therapies needs to be improved3–5.
Multiple trastuzumab-resistance mechanisms have been identi-
ﬁed in preclinical studies, in which constitutive activation of the
PI3K pathway owing to PTEN deﬁciency or PIK3CA mutations
seems to be one of the most prevalent events6–8. The better
understanding of breast cancer biology has been translated
into the development of new anti-HER2 agents with varying
mechanisms of action9,10. The small molecular tyrosine kinase
inhibitor lapatinib has demonstrated activity in HER2+ meta-
static breast cancer and in the preoperative setting11,12. Pertu-
zumab, a monoclonal antibody with a distinct binding site from
trastuzumab, inhibits receptor dimerization13,14. The addition
of pertuzumab to combination therapy has led to improved
progression-free survival in patients with HER2+ metastatic
breast cancer and higher response rates in the preoperative
setting14.
To maintain genome stability, eukaryotic cells have evolved
with the ability to detect and translate the initial signals of
DNA damage to proper cellular responses. The key components
of the DNA damage response (DDR) include ATM (ataxia-
telangiectasia mutated), ATR (ataxia-telangiectasia and Rad3-
related), and DNA-PKcs (DNA dependent protein kinase cata-
lytic subunit)15. These kinases initiate DNA damage signaling
cascades and activate cell cycle checkpoints and DNA repair16,17.
Advanced tumors often show inactivation of DDR markers,
suggesting that silencing of the DDR is an important prerequisite
for cancer progression. The wildtype p53-induced phosphatase
1 (WIP1, also known as PPM1D) functions as a homeostatic
regulator and a master inhibitor of the DDR. It is a type 2C
serine/threonine phosphatase that is induced in response to
DNA damage in a p53-dependent manner. Previous studies
demonstrated that WIP1 dephosphorylates multiple key proteins
in the DDR, such as CHK1, CHK2, p53, MDM2, and H2AX18.
Importantly, WIP1 suppresses p53 by multiple mechanisms,
including dephosphorylation of p53 kinases (CHK1, CHK2),
p53 itself, and MDM2.
Consistent with its oncogenic functions, the WIP1 gene in the
17q23 chromosome region is ampliﬁed and overexpressed in
11–18% of human breast cancer18,19. The WIP1-null mice are
resistant to spontaneous and oncogene-induced tumors due to
enhanced DNA damage and p53 responses20,21. While previous
studies ruled out the possibility of any protein-coding oncogenes
in the WIP1-containing 17q23 amplicon, we identiﬁed an onco-
genic miRNA gene, MIR21, in almost all the WIP1 amplicons.
Moreover, a majority of the WIP1/MIR21-ampliﬁed cancer
samples have concurrent HER2 ampliﬁcation. Here we showed
that the chromosome 17q23 ampliﬁcation in the HER2+ breast
cancer results in aberrant elevation of WIP1 and miR-21, which
not only contributes to breast tumorigenesis, but also causes
resistance to anti-HER2 therapy. Therefore, targeted inhibition
of WIP1 and miR-21 could be an effective therapeutic approach
for trastuzumab-resistant HER2+ breast cancer.
In this study, we propose to develop a therapy for
trastuzumab-resistant HER2+ breast cancer with the combined
use of a small molecular inhibitor against WIP1 (GSK2830371),
anti-miR-21 oligonucleotides (antagomiR21), and trastuzumab.
However, GSK2830371 has poor solubility in water with poor
bioavailability in vivo22. Although antagomiR21 is highly
soluble in water, it is relatively unstable in blood. Furthermore,
neither GSK2830371 nor antagomiR21 can efﬁciently enter cells
by itself. To address these challenges, we developed a nano-
particle system using biocompatible polymers, to co-
encapsulate GSK2830371 and antagomiR21 for targeted co-
delivery into HER2+ breast tumor. A major hurdle to
nanoparticle-based delivery of RNAs (including antagomiR21)
is that the RNAs can be easily degraded by the many RNases in
endo/lysosomes after cell uptake of the RNA-laden nanoparticle
by endocytosis23. This challenge can be overcome with our
nanoparticle because it has the nanobomb effect when exposed
to the low pH in endo/lysosomes to break up the endo/lyso-
somes. As a result, the antagomiR21 can escape the endo/
lysosomes into the cytosol (where it performs its function)
before degradation. We show that the combined treatment with
WIP1 and miR-21 inhibitors using the nanoparticle sig-
niﬁcantly reduces trastuzumab-resistant HER2+ tumor growth,
conﬁrming that co-inhibition of WIP1 and miR-21 is a pro-
mising therapeutic strategy.
RESULTS
Co-ampliﬁcation of WIP1 and MIR21 in the 17q23 amplicon.
The WIP1-containing 17q23 region is ampliﬁed in a subset
(~11%) of human breast tumors24. Extensive analyses of breast
cancer genomics revealed that the 17q23 amplicon can span up
to over 10Mb, including a number of protein-coding and non-
coding genes. Early studies identiﬁed WIP1 as the only oncogene
in the amplicon due to incomplete breast cancer genomic data-
bases and lack of noncoding RNA information19,24. To search
for other potential driver oncogenes, the 17q23 amplicon was
analyzed using TCGA (The Cancer Genomics Atlas) breast
cancer databases25,26. Our results revealed that the amplicon
region focuses on an approximately 2.73 Mb region (Fig. 1a),
where 21 protein-coding genes (MED13, INTS2, BRIP1, NACA2,
TBX4, C17ORF82, TBX2, BCAS3, APPBP2, C17ORF64, USP32,
CA4, HEATR6, RNFT1, RPS6KB1, TUBD1, VMP1, PTRH2,
CLTC, DHX40, YPEL2) and 3 miRNA genes (MIR4737, MIR21,
MIR4729) showed highly similar ampliﬁcation proﬁles to WIP1
(Fig. 1b). Transgenic mice overexpressing WIP1 in mammary
glands showed no abnormal overt phenotype and did not develop
spontaneous mammary tumors27. However, their mammary
tumor incidence was accelerated in the presence of the ErbB2
(the mouse homolog of HER2) transgene, suggesting that WIP1
plays an important role in HER2-initiated breast cancer. Inter-
estingly, we found that the WIP1 ampliﬁcation was enriched in
human HER2+ breast cancer (Fig. 1c). While only 10% of all
types of breast cancer in the dataset were identiﬁed as HER2+,
the HER2+ subtype existed in 30% (3-fold more, p= 3.6e−13) of
the WIP1-ampliﬁed breast cancers, compared to 7% of breast
cancers without WIP1 ampliﬁcation (Fig. 1c). We found that
14 out of 24 genes in the amplicon were signiﬁcantly (p < 0.001)
overexpressed with the gene ampliﬁcation. WIP1, as well as
MIR21, a well characterized oncomiR, were both overexpressed,
similar to the aberration of HER2 (ERBB2) (Fig. 1d and Supple-
mentary Fig. 1a–c). Consistently, the expression levels of WIP1
and miR-21 were also signiﬁcantly upregulated in ErbB2-trans-
genic mice when compared to their normal littermates, although
depletion of WIP1, miR-21 or both only had minimal effect on
the ErbB2 expression (Supplementary Fig. 1d–h). Furthermore,
we assessed the transformation ability of the 14 genes that are
overexpressed in the 17q23-ampliﬁed breast cancers (Fig. 1e and
Supplementary Fig. 2). Soft-agar colony formation assays were
performed by transducing primary mammary epithelial cells from
MMTV-ErbB2 transgenic mice with lentivirus expressing each
individual gene. These results demonstrated that both WIP1 and
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07264-0
2 NATURE COMMUNICATIONS |          (2018) 9:4718 | DOI: 10.1038/s41467-018-07264-0 | www.nature.com/naturecommunications
aChr17
Br
ea
st
 in
va
si
ve
ca
rc
in
om
a 
ERBB2
17q23 Amp 2.73 Mb
YP
EL
2
M
IR
21
US
P3
2
TB
X2
M
ED
13
W
IP
1
–2
0
2
d
10
15
20
Lo
ss
Ne
utr
al
Ga
in
Am
p
ER
BB
2 
(R
NA
Se
q)
16
18
20
M
IR
21
 (m
iR
NA
Se
q)
P-value = 5.5E−99
P-value = 4.8E−12
P-value = 8.1E−151
8
12
16
W
IP
1 
(R
NA
Se
q)
b
From 17q22 to 17q23.3
0.4
0.6
0.8
1
YPEL2 MED13
WIP1
MIR21
Am
p 
sim
ila
rit
y 
wi
th
 W
IP
1
c
Without 17q23 Amp
7%
17q23 Amp
30%
p = 3.6e–13
10%
HER2+
Others
All BRCA patients
14%
17q23 Amp
All BRCA patients
e
N
o.
 c
ol
on
ie
s 
pe
r w
el
l
Ctr
l
ME
D1
3
INT
S2
WI
P1
AP
PB
P2
US
P3
2
HE
AT
R6
RN
FT
1
RP
S6
KB
1
TU
BD
1
MI
R2
1
VM
P1
PT
RH
2
CL
TC
DH
X4
0
HR
AS
0
500
1000
1500
***
**
**
Fig. 1 Association between gene ampliﬁcation, gene expression and HER2+ breast cancer on chromosome 17. a Heatmap of genomic segment copy-
number abnormalities (log-ratio measurements) of human chromosome 17 in 1,080 breast invasive carcinomas. Positive log-ratios indicate degree of copy
number gain (red) whereas negative values mark the loss (blue). b Co-ampliﬁcation ofWIP1 and genes from 17q22 to 17q23. c HER2+ subtype signiﬁcantly
enriched in breast cancers harboring WIP1-contating 17q23 amplicon. The TCGA dataset was downloaded from Xena Public Data Hubs (see Methods
for details). d Correlation between gene expression aberration and copy number variation for genes, WIP1, MIR21, and HER2 (ERBB2) in breast tumors.
e Soft agar colony formation assays with MMTV-ErbB2 mouse mammary epithelial cells transduced with control vector (Ctrl) or lentiviral vector
expressing the indicated genes. **p < 0.01; ***p < 0.001; unpaired 2-tailed t-test was used (d, e). Data are presented as mean ± SD and are representative
of 3 independent experiments
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MIR21, but not any other genes in the amplicon, induced in vitro
transformation, indicating their functional roles in HER2+ breast
cancers.
Depletion of miR-21 and WIP1 inhibits mammary tumor-
igenesis. Both WIP1−/− and MIR21−/− mice are known to
have normal mammary gland development and functions21,24,28,
suggesting that WIP1 and miR-21 are dispensable for develop-
mental and physiological functions. To study their potential
oncogenic roles, mammary tumorigenesis of MMTV-ErbB2
transgenic mice were examined in the contexts of WIP1 or
MIR21 knockout (Fig. 2a). All the females in the experimental
groups were kept virgin during the 20-month observation period.
All the MMTV-ErbB2 transgenic female mice (12 out of 12) died
of mammary tumors before the end of observation period.
We found that knockout of WIP1 impaired the ErbB2-induced
mammary tumorigenesis, consistent with previous studies20,21.
Similar to the WIP1 knockout, depletion of miR-21 rendered
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Fig. 2 Suppression of miR-21 and WIP1 inhibits proliferation and tumorigenic potential of HER2+ breast cancer cells. a Kaplan–Meier analysis of tumor-free
survival in female MMTV-ErbB2 wild type (n= 12), MMTV-ErbB2; WIP1−/− (n= 12) and MMTV-ErbB2; MIR21−/− (n= 13) mice. b Ampliﬁcation of MIR21
and WIP1 is associated with poor overall survival in patients with HER2+ breast cancer, but not with patients with luminal A, luminal B or basal-like breast
cancer. c Cell growth curve of H605 cells (MMTV-ErbB2 tumor cells) expressing doxycline (Dox)-inducible control shRNA or speciﬁc shRNA targeting
WIP1 or mature miR-21. dMammosphere formation assay in H605 cells expressing Dox-inducible control shRNA, speciﬁc shRNA targeting WIP1 or mature
miR-21. Right panel demonstrates the quantitative data using Image J software. Scale bar, 500 µm. *p < 0.05; ***p < 0.001**; ***p < 0.001; Log-rank
Mantel–Cox test (a, b) and one-way ANOVA followed by Tukey’s t test (c, d) were used. Data are presented as mean ± SD and are representative of
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the MMTV-ErbB2 mice considerably more resistant to tumor
formation. Only 6 out of 13 MIR21-/-;MMTV-ErbB2 females
developed mammary tumors (p < 0.001). Overall, WIP1−/−;
MMTV-ErbB2 and MIR21−/−;MMTV-ErbB2 females showed a
signiﬁcant increase in lifespan in comparison with their control
MMTV-ErbB2 littermates. In line with these mouse studies,
analysis of human breast cancer genomics using TCGA databases
showed that copy number gains of WIP1 or MIR21 are sig-
niﬁcantly correlated with poor clinical outcomes in patients with
HER2+ breast cancer, but not in patients with luminal A, luminal
B or basal-like breast cancer (Fig. 2b). We next assessed whether
inhibiting WIP1 or miR-21 impact the proliferation and mam-
mosphere formation of the mouse tumor cell line H605, which
was isolated and established from a mouse MMTV-ErbB2
mammary tumor29. Either WIP1 or miR-21 knockdown mark-
edly reduced the tumor cell growth rate, whereas knockdown
of both had a more profound inhibition of cell proliferation
(Fig. 2c and Supplementary Fig. 3a, b). We also found that
depletion of WIP1 or miR-21 signiﬁcantly diminished the num-
ber and size of mammospheres formed by H605 cells, and
knockdown of both WIP1 and miR-21 further inhibited the
mammosphere formation (Fig. 2d). In addition, depletion of
WIP1, miR-21 or both promoted G1/S phase arrest and apoptosis
(Supplementary Fig. 3c, d). These results validated the oncogenic
potential of both WIP1 and MIR21 genes.
Oncogene-induced senescence (OIS) in mammary glands is a
protective mechanism against breast tumorigenesis30. Accumu-
lating evidence supported an important role of the ATM-p53
signaling pathway in OIS31. However, recent study pointed
out that TGF-β signaling pathway is responsible for the ATM-
independent OIS in mammary glands32. While WIP1 is a master
inhibitor for the ATM-p53 signaling, we found that miR-21 may
suppress the TGF-β signaling. To identify physiologically relevant
miR-21 targets, we analyzed genome-wide gene expression
proﬁles in mammary epithelial cells (MMECs) isolated from
MIR21-/-;MMTV-ErbB2 female mice and their wildtype litter-
mates. Gene transcripts were identiﬁed as potential miR-21
targets in MMECs, which are most signiﬁcantly increased in the
MIR21-/- cells and modulate crucial tumor cell activities (Fig. 3a
and Supplementary Fig. 4). There is signiﬁcant overlap between
in silico predicted miR-21 target genes and those genes up-
regulated in the MIR21−/− MMECs (Supplementary Fig. 4a).
Interestingly, a number of miR-21 targets are associated with the
TGF-β signaling pathway, including MAP2K3, BMPR1B,
INHBA, MAP2K4, MAPK1, MAPK8, NRAS, SMAD2, SMURF2
and SOS1 (Fig. 3a). TGF-β/SMAD signaling pathways are among
the most enriched pathways regulated by miR-21 (Supplementary
Fig. 4b). We performed individual gene expression analyses to
validate these target genes in MIR21+/+ and MIR21−/− mouse
mammary glands. Mouse mammary glands were harvested from
8-week littermate females and the puriﬁed mRNAs were
subjected to reverse transcription and quantitative PCR analyses
(Fig. 3b). While WIP1 plays a primary role in the DDR and DNA
repair, no signiﬁcant overlaps were identiﬁed between WIP1 and
miR-21 targets, suggesting that these two oncogenes play non-
redundant roles in mammary tumorigenesis. In addition,
MMECs, isolated from MMTV-ErbB2 transgenic mouse, were
passaged and examined for OIS. The MMECs, after three
passages, exhibited an increase in cell size, cell spreading,
vacuolization, multinucleated morphology and positive staining
for senescence-associated β-galactosidase (SA-β-Gal) activity
(Fig. 3c). Ectopic expression of WIP1 or miR-21 alone partly
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rescued MMECs from senescence, indicated by reduced number
of cells positive for SA-β-Gal. Co-expression of WIP1 and miR-21
had a profound inhibition on the OIS of the MMECs over-
expressing ErbB2, suggesting that ampliﬁcation of WIP1 and
miR-21 may allow MMECs to overcome OIS in oncogenic
transformation.
Co-ampliﬁed DDX5 facilitates pri-miR-21 maturation. While
no miRNA-sequence speciﬁcity exists for Drosha and DGCR8,
two core components, in the microprocessor, emerging evidence
has shown that regulatory RNA-binding proteins in the Drosha
complexes may recruit speciﬁc primary miRNAs (pri-miRs) for
processing33. We performed a MS2-TRAP (MS2-tagged RNA
afﬁnity puriﬁcation) assay to identify a pri-miR-21-speciﬁc reg-
ulatory component in the Drosha microprocessor34. The assay is
based on the addition of a speciﬁc MS2 RNA hairpin loop
sequence (from bacteriophage MS2) to pri-miR-21, followed by
co-expression of the MS2-tagged RNA together with GST-tagged
MS2P that speciﬁcally binds the MS2 RNA sequence. In addition
to those predicted proteins (Drosha and DGCR8) in the micro-
processor complex, DEAD-Box helicase 5 (DDX5) was identiﬁed
in the pri-miR-21-protein complex (Supplementary Fig. 5a).
Interaction of DDX5 with Drosha was further conﬁrmed in the
immunoprecipitation and western blotting assay (Fig. 4a). DDX1,
identiﬁed in our previously study35, was used as a positive control
for the interaction with Drosha. RNA immunoprecipitation (RIP)
assays further veriﬁed speciﬁc interaction between DDX5 and pri-
miR-21 (Fig. 4b). As a positive control, pri-miR-16 was reported
as a DDX5-interacting RNA36. Pri-miR-200a was used as a
negative control that had no interaction with DDX535. Knock-
down of DDX5 inhibited the processing of pri-miR-21 and
resulted in accumulation of unprocessed pri-miR-21 and
decreased levels of mature miR-21 in three breast cancer cell lines
harboring 17q23 amplicon (Fig. 4c and Supplementary Fig. 5b).
Interestingly, genomic analysis of HER2+ breast cancer revealed
that DDX5 is adjacent to the WIP1-MIR21 amplicon and is co-
ampliﬁed in 67% of HER2+ breast cancer with MIR21 ampliﬁ-
cation. Consistent with the analysis of miR-21 and DDX5 mRNA
expression levels using TCGA datasets (Supplementary Fig. 5c),
DDX5 protein levels are positively correlated with miR-21 levels,
determined by immunohistochemistry staining of HER2+ breast
tumor tissue microarray (Fig. 4d and Supplementary Fig. 5d).
Using colony formation assay, we found that overexpression of
DDX5 signiﬁcantly promoted anchorage-independent cell growth
compared to the control, which was abrogated by silencing of
miR-21, but not miR-16 (Fig. 4e). Collectively, DDX5 is poten-
tially an important player that promotes the oncogenic function
of the 17q23 amplicon via facilitating miR-21 maturation.
Inhibition of WIP1 and miR-21 kills HER2+ breast cancer
cells. WIP1 is a major inhibitor for the activity of p5337. Thus,
inhibiting WIP1 may impact the survival of HER2+ breast cancer
cells in a p53-dependent manner. HER18 cells bearing wildtype
p53 were highly sensitive to the treatment of the WIP1 inhibitor
GSK2830371, which markedly increased the levels of phos-
phorylated CHK2 and p21 (Fig. 5a). However, both of the
HER2+ breast cancer cell lines with mutant p53 (BT474
and MDA-MB453) were insensitive to the inhibition of WIP1
(Fig. 5b, c), although they also have 17q23 amplicon. By contrast,
treatment of antagomiR21 signiﬁcantly reduced the cell pro-
liferation and viability of these HER2+/p53-mutant cells (Fig. 5d,
e). Furthermore, inhibition of miR-21 dramatically sensitized
HER18 cells to the treatment of the WIP1 inhibitor (Fig. 5d).
These results suggest that inhibiting miR-21 is a potentially
therapeutic approach to target breast cancers harboring 17q23
ampliﬁcation regardless of p53 mutations.
Multiple trastuzumab resistance mechanisms have been
identiﬁed, in which activation of the PI3K pathway seems to be
the most prevalent. In line with the previous report concerning
the function of miR-21 in negative regulation of PTEN38, we
also found that miR-21 directly inhibited PTEN in MMECs
(Fig. 3a, b). Hence we reasoned that inhibiting miR-21 may
sensitize HER2+ breast cancer cells to the treatment of
trastuzumab. Trastuzumab-resistant cell lines were generated
from parental BT-474 and HER18 lines via the treatment of
escalating doses up to 15 µg ml−1 of trastuzumab (Fig. 6a, b).
The half maximal inhibitory concentration (IC50) was increased
by ~10-fold in both resistant cell lines. Treatment of trastuzumab
inhibited cell proliferation (increased p27 levels) and AKT
signaling pathway (reduced pAKT levels) in parental BT-474
and HER18 cells, which were not observed in the resistant cells
(BT-474R and HER18R) (Fig. 6a, b). Knockdown of miR-21
notably inhibited the AKT signaling as expected and suppressed
cell proliferation. Moreover, we observed that miR-21 depletion
markedly sensitized both BT-474R and HER18R cells to the
treatment of trastuzumab, indicating the p53-independent
activity of miR-21 inhibition. By contrast, knockdown of
WIP1 had a similar effect on the resistant cells expressing
wildtype p53 (HER18R), but not on the p53-mutant BT-474R
cells (Fig. 6c, d). To test whether inhibiting WIP1 and miR-21
had synergistic effects, HER18R cells were treated with the
WIP1 inhibitor, antagomiR21 or both inhibitors, along with a
low concentration of trastuzumab (1 µg ml−1) (Fig. 6e). While
they were insensitive to trastuzumab as single agent, HER18R
cells were sensitized by miR21 inhibitor or WIP1 inhibitor
alone, but the effects were drastically magniﬁed by treatment
with both inhibitors.
To further test the suppressive effect of WIP1 and miR-21
inhibition on breast tumor growth in vivo, HER18R cells
expressing doxycycline (Dox)-inducible control, WIP1, miR-21
or DDX5 short-hairpin RNAs (shRNAs) (>70% knockdown
efﬁciency) were injected to mouse mammary fat pads to establish
xenograft breast tumor models in female nonobese diabetic/
severe combined immunodeﬁciency (NOD/SCID) mice. Knock-
down efﬁciency of WIP1, miR-21, and DDX5 shRNAs was
conﬁrmed in the HER18R cells (Supplementary Fig. 6a, b). Once
tumors were established at three weeks after transplantation, the
tumor-bearing mice were treated with 5 mg kg−1 of trastuzumab.
While the HER18R tumors were resistant to the trastuzumab
treatment as expected, in comparison with the trastuzumab
sensitivity of the HER18 tumors. Depletion of miR-21 or WIP1
markedly decreased the growth of xenograft tumors (Fig. 6f, g
and Supplementary Fig. 6c, d), and their dual depletion led
to more severe tumor growth inhibition, indicating a synergistic
role of miR-21 and WIP1 in the trastuzumab resistance of
HER2+ breast cancer. Notably, inhibition of DDX5 also exhibited
modest effect on the inhibition of HER18R tumor growth,
supporting its role in promoting miR-21 expression and other
documented oncogenic functions39.
Nanoparticles for co-delivery of miR-21 and WIP1 inhibitors.
The nanoparticle was synthesized using four biocompatible
materials (three polymers and one phospholipid) approved by
the U.S. Food and Drug Administration (FDA) for medical
use (Fig. 7a): Poly(d,l-lactide-co-glycolide) (PLGA), Pluronic
F127 (PF127), chitosan, and 1,2-dipalmitoyl-sn-glycerol-3-phos-
phocholine (DPPC). To generate the nanobomb effect, chitosan
was modiﬁed with guanidine group to form chitosan-guanidine
(CG)40. The guanidine group can react reversibly with carbon
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dioxide (CO2) to form chitosan-guanidinium (CG-CO2) in a
pH-dependent manner (Fig. 7a)41, which may be utilized to
capture/store CO2 at neutral pH and release at acidic pH. To
synthesize the nanoparticle, the aqueous solution of CG was
bubbled with CO2 gas to form CG-CO2 and then mixed with
antagomiR21. The aqueous mixture was emulsiﬁed with organic
solvent or oil (dichloromethane: tetrahydrofuran 40:1) containing
DPPC, PLGA, and GSK2830371 to form a water-in-oil structure,
where the CG-CO2 and oligonucleotides were encapsulated in
the aqueous core while PLGA, DPPC, and GSK2830371 were
in the surrounding oil. Next, the ﬁrst emulsion was emulsiﬁed
with the aqueous solution of PF127-Chitosan (P127 modiﬁed
with chitosan42, which served as the stabilizer during the
second emulsion). The organic solvent was then evaporated to
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produce the two agents (inhibitors of miR-21 and WIP1)-laden
nanoparticles (in-MW@NP).
The resulting nanoparticles have a smooth spherical morphol-
ogy and core-shell structure with diameter of 115 ± 9.7 nm at
pH 7.4 (Fig. 7b). At pH 6.0, defect (dark spots) can be seen on
the shell of some nanoparticles. Under more acidic pH 4.0,
extensive defects can be seen in most of the nanoparticles and
they forms large aggregates owing to the low pH-activated
nanobomb effect of the nanoparticles (Fig. 7b and Supplementary
Fig. 7a, b). More speciﬁcally, the CG-CO2 encapsulated in in-
MW@NP can generate/release CO2 gas at the reduced pH to
break up the nanoparticles, and the severely damaged nanopar-
ticles may tangle together to form large aggregates.
The stability of antagomiR21 encapsulated in the nanoparticles
was examined by incubating it in serum at 37 °C (Fig. 7c). The
oligonucleotide encapsulated in in-MW@NP was observable even
after 36 h of incubation, while the free (non-encapsulated)
oligonucleotide started to degrade in a few minutes and
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disappeared in less than 2 h. By contrast, there was no notable
degradation within at least 6 h when the free oligonucleotides
were incubated with RNase-free buffer (Supplementary Fig. 7c).
A detergent (1% alconox, w/v) was used to treat the NPs as
a positive control for the release of antagomiR21. After 6 h
incubation, there was a sharp band of free antagomiR21 observed,
indicating the release of antagomiR21 from nanoparticles
(Supplementary Fig. 7c). These results suggest that the nano-
particle could protect the antagomiR21 from degradation by
serum RNases at neutral pH. To study the low pH-activated
g
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nanobomb effect of in-MW@NP, Dextran (molecular weight of
10 KDa, similar to that of the antagomiR21) labeled with
Rhodamine (Dex-Rho) was used in the nanoparticle (DexR-
ho@NP). After incubating the nanoparticles with trastuzumb-
resistant HER18R breast cancer cells for 1–6 h, the intracellular
distribution of Rhodamine (red ﬂuorescence) was examined
against lysotracker (green ﬂuorescence) that stains the endo/
lysosomes. The red and green ﬂuorescence largely overlapped
after incubating for 1 and 3 h (Fig. 7d), indicating that the cells
take up the nanoparticles mainly by endocytosis. However, their
overlap became minimal at 6 h, indicating successful escape of
Dex-Rho from endo/lysosomes, probably due to the low pH-
activated nanobomb effect to break open the endo/lysosomes.
By contrast, cellular uptake of free Dex-Rho was minimal even
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after 6 h of incubation and it largely localized to endo/lysosomes
(Fig. 7d). Collectively, it is clear that the CG-CO2 encapsulated in
the nanoparticle can disrupt the endo/lysosomes under low pH by
generating CO2, which greatly enhance the cytosolic delivery of
antagomiR21.
Anti-tumor activity of co-delivered miR-21 and WIP1 inhibi-
tors. We next examined if the miR-21 and WIP1 inhibitors-laden
nanoparticles are effective in killing trastuzumb-resistant breast
cancer cells. First, we investigated the anticancer capacity of the
drug-laden nanoparticles in vitro (Fig. 8a). HER18R cells were
treated with free WIP1/miR-21 inhibitors, blank nanoparticles,
and various amounts of in-MW@NP for a total of 72 h and the
cell viability was measured. The blank nanoparticles were not
detrimental to the cells and did not impact the cell growth,
suggesting their minimal cytotoxicity. Although the aggregation
of NPs was found in the low pH buffer due to the CO2 generation
and NPs disruption (Fig. 7b and Supplementary Fig. 7a), non-
speciﬁc effects on cellular functions were not observed because
the CO2 generation of the NPs, unlike in the buffer solution, only
d
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occurs when they are in the endo/lysosomes. In this case, the NPs
aggregation should be minimal in the cell. The drug-laden
nanoparticles were signiﬁcantly more cytotoxic to the
trastuzumab-resistant HER18R cells than free WIP1 or miR-21
inhibitors due to the enhanced drug delivery and release of the
nanoparticles.
We next investigated the tumor-targeting capability of the
nanoparticles in mice. Indocyanine green (ICG) was encapsulated
in the nanoparticles for in vivo imaging. Highly enhanced
ﬂuorescence of ICG was observable in tumor at 6 h after
intravenous injection of the nanoparticles, compared to free
ICG (Fig. 8b). We further checked the ﬂuorescence of ICG at 24
h, the ICG-laden nanoparticles were exclusively localized in the
tumor, while no notable signal was seen for free ICG. Various
organs were harvested for ex vivo imaging to check the
biodistribution of ICG after sacriﬁcing the mice at 24 h. Indeed,
only tumors from the nanoparticles treated groups showed strong
ﬂuorescence of ICG, in comparison with the tumors from the
saline or free ICG-treated mice. As expected, weak ﬂuorescence
was observed in the liver from mice treated with free ICG or ICG-
laden nanoparticles probably due to minimal nonspeciﬁc uptake
and retention. The stronger signal present in the liver in the
ex vivo than in vivo probably due to the penetration depth of
ﬂuorescence. We further investigated the anti-tumor efﬁcacy and
safety of the WIP1 and/or miR-21 inhibitor-laden nanoparticles
in vivo by treating orthotopic HER18R or BT-474R mammary
tumor-bearing mice. When tumor reached a volume of ∼50 mm3,
the tumor-bearing mice were divided randomly into four groups:
blank nanoparticles, WIP1 inhibitor-laden nanoparticles,
antagomiR21-laden nanoparticles, and WIP1+miR-21
inhibitors-laden nanoparticles. Mice were treated with antag-
omiR21 (1.0 mg kg–1) and/or WIP1 inhibitor (5.0 mg kg–1)
encapsulated in the nanoparticles via intravenous injection twice
weekly. Inhibiting WIP1 or miR-21 by their inhibitor-laden
nanoparticles both signiﬁcantly inhibited the mammary tumor
growth with ~60% of reduction in tumor volumes and ~50% of
reduction in tumor weights (Fig. 8c–e). For the HER18R tumor
bearing wild type p53, dual inhibition of WIP1 and miR-21
exhibited the best anti-tumor capacity with over 95% of tumor
growth inhibition when compared with the tumor from the
control group (Fig. 8c–e). However, for the BT-474 tumor
harboring mutant p53, inhibition of miR-21 signiﬁcantly
impaired mammary tumor growth although WIP1 inhibitor only
had a modest effect (Supplementary Fig. 8a–c). In addition, we
also analyzed the effect of WIP1 or miR-21 inhibition on tumor
metastasis by intravenously injecting HER18R cells into female
nude mice. Knockdown of WIP1 or miR-21 alone showed
signiﬁcant reduction in lung metastasis, whereas inhibition of
both had a more profound reduction of lung nodules (Supple-
mentary Fig. 8d–f), suggesting that inhibiting WIP1 and miR-21
is a promising therapeutic approach for both primary and
metastatic tumors. Inhibiting miR-21 and WIP1 resulted in
profound apoptosis in the HER18R tumor cells, as well as
signiﬁcant suppression of cancer cell proliferation (Fig. 8f, g and
Supplementary Fig. 8g). Importantly, we did not notice any
evident side effect of the drug-laden or blank nanoparticles.
Neither death nor signiﬁcant drop of body weight was noted for
the mice treated with saline, blank nanoparticles, and all the three
drug formulations (WIP1 inhibitor, miR-21 inhibitor, and WIP1/
miR-21 inhibitors) (Supplementary Fig. 8h), suggesting the
excellent safety of the nanoparticles for targeted delivery of
WIP1 and miR-21 inhibitors in vivo.
Discussion
There is substantial evidence to support the oncogenic properties
of WIP1, but much less is known regarding the clinical sig-
niﬁcance of WIP1 aberrations in human cancers. Although the
WIP1 ampliﬁcation is closely correlated with poor clinical out-
come, the WIP1 transgene itself fails to promote mammary
tumorigenesis in mice22,43. Here, in-depth analysis of the human
17q23 amplicon revealed that MIR21 is the other potential
oncogene that may cooperate with WIP1 in mammary tumor
initiation and progression. This ﬁnding is important because
WIP1 and miR-21 deactivate two major tumor suppression
pathways: p53 and PTEN pathways, respectively. We also made a
clinically signiﬁcant ﬁnding that theWIP1/MIR21 ampliﬁcation is
enriched in HER2+ breast cancer, suggesting that WIP1/miR-21
aberrations cooperate with HER2 in tumors with poor prognosis.
Aberrant expression of WIP1 and miR-21 may promote breast
tumorigenesis by inhibiting OIS in mammary epithelial cells. OIS
is a key anti-cancer barrier at the early stage of tumorigenesis,
which involves the ATM-p53 and TGF-β signaling pathways in
mammary glands. While the importance of the ATM-p53 sig-
naling has been extensively studied, recent evidence shows that
the TGF-β signaling is responsible for the ATM-independent OIS
in mammary glands32. Although WIP1 is a master inhibitor in
the ATM-p53 signaling, overexpression of WIP1 in transgenic
mice does not induce mammary tumorigenesis, suggesting that
intact TGF-β signaling needs to be overcome for breast cancer
initiation. We found that miR-21 is probably a potent inhibitor of
the TGF-β pathway by suppressing a number of key components
in the pathway. Our results suggest that WIP1 and miR-21
cooperatively inhibit these two pathways to override OIS and
promote mammary tumorigenesis.
Post-transcriptional processing of pri-miRNAs is an essential
step in miRNA biogenesis. While Drosha and DGCR8 are the
core components in the microprocessor, neither of them has
binding speciﬁcity for individual pri-miRNAs44–46. We identiﬁed
DDX5 as a miR-21-speciﬁc regulator in the Drosha micro-
processor. Thus, co-ampliﬁcation of DDX5 with MIR21 facilitates
the efﬁcient processing of pri-miR-21 transcripts and results in
elevated levels of miR-21. This hypothesis is also supported by the
positive correlation between DDX5 copy numbers and miR-21
levels in mammary tumor tissues. In addition to its role in
miRNA processing, DDX5 is an essential gene in the develop-
ment as DDX5 knockout mice are embryonically lethal47. By its
interaction with mRNA, DDX5 is also involved in the processing,
splicing and degradation of mRNA. Mazurek and colleagues
reported that DDX5 directly regulates DNA replication factor
expression by promoting the recruitment of RNA polymerase II
to E2F-regulated gene promoters39. DDX5 was suggested as a
promising candidate for targeted therapy of breast tumors with
DDX5 ampliﬁcation. In line with their study, we showed that
inhibiting DDX5 suppressed the growth of HER2+ tumors
in vivo, suggesting that DDX5 is likely one of the important
regulators for mammary tumors induced by 17q23 ampliﬁcation.
Although RNA interference (RNAi) has shown as a promising
therapeutic strategy for cancer, few RNAi-based therapies have
passed/entered Phase II/III clinical trial48–50. This is partly
because naked RNAs have poor stability in blood, do not enter
cells, and are instable in the endo/lysosome inside cells23. In
addition, the small molecule drugs for conventional chemother-
apy is either insoluble in water or can diffuse to both normal
tissue and tumor, which may induce signiﬁcant side effects51.
Nanotechnology have demonstrated great potential for over-
coming the challenges facing conventional chemo/RNAi ther-
apy51–53. In this study, we designed and synthesized a unique
nanoparticle to encapsulate both WIP1 and miR-21 inhibitors for
combination therapy. It not only can improve the solubility and
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bioavailability of GSK2830371 for inhibiting WIP1 but also
achieve cytosolic delivery of antagomiR21. The nanoparticle
could stabilize antagomiR21 by preventing it from the enzymatic
degradation during circulation and preferentially targets tumor.
After entering tumor, it could enhance cellular uptake of the
encapsulated agents. More importantly, after being taken up by
cancer cells via endocytosis, the nanoparticle could generate
carbon dioxide gas to break open endo/lysosomes. Moreover, our
nanoparticle-based approach ensures that the dose ratio of the
two agents in the tumor can be maintained to be the same as that
at injection, while the dose ratio of the two agents in tumor may
be very different from that at injection due to vast difference in
bioavailability of the hydrophobic GSK2830371 and hydrophilic
antagomiR21. This well-designed nanoparticle is an excellent
vehicle for delivering the antagomiR21 (and other RNAs) to
overcome both the extracellular and intracellular barrier to the
use of RNAs for cancer therapy.
In summary, we identiﬁed that co-ampliﬁcation of MIR21 and
WIP1 in HER2+ breast cancer harboring 17q23 amplicon gen-
erates therapeutic vulnerabilities and provides an effective treat-
ment strategy for breast cancers containing such genomic events.
We demonstrated that miR-21 and WIP1 functionally cooperate
with the HER2 gene in breast tumorigenesis, and that inhibiting
them circumvents resistance to anti-HER2 therapies. It is
anticipated that development of nanoparticles encapsulating
miR21 and WIP1 inhibitors will facilitate this promising ther-
apeutic approach in treating trastuzumab-resistant breast cancers.
Methods
TCGA analysis. The TCGA breast cancer data were downloaded from the website:
https://xenabrowser.net/datapages/?cohort= TCGA%20Breast%20Cancer%20
(BRCA), which include copy number variation (CNV) at segment level in log-ratio,
CNV at gene level estimated by using the GISTIC2 algorithm, miRNA mature
strand expression data in logarithm (base-2), and patient information about HER2
positive or negative. To study the ampliﬁcation (Amp) similarity between other
genes and WIP1, we focused on only patients with WIP1 ampliﬁcation. The ratio
of WIP1-Amp patients with Amp on the gene as well was calculated to represent
such similarity between the gene and WIP1.
Tissue culture. MCF-7, MDA-MB453, BT474, HMC18, MDA-MB231, MCF10A
cell lines were purchased from the American Type Culture Collection. HER18 cells
(stably overexpress HER2 and were derived from MCF-7) were a gift from Dr.
Mong-Hong Lee (MD Anderson Cancer Center). These cell lines were maintained
in Dulbecco’s Modiﬁed Eagle Medium (DMEM) with 10% FBS at 37°C in 5% CO2.
MCF10A cells were maintained in DMEM/F12 supplemented with 5% Horse
Serum, epidermal growth factor (20 ng ml−1), Hydrocortisone (0.5 mgml−1),
Cholera Toxin (100 ng ml−1) and Insulin (10 μg ml−1). BT474 and HER18 cells
were grown and selected in 10 ug ml−1 Trastuzumab for several weeks and deﬁned
as trastuzumab-resistant cells (HER18R, BT474R). Cell lines were banked in
multiple aliquots on receipt to reduce risk of phenotypic drift and were tested
negative for mycoplasma contamination using the Mycoplasma detection kit
(Lonza). Cell identity was conﬁrmed by validating the STR DNA ﬁngerprinting
using the AmpFLSTR Identiﬁler Kit according to the manufacturer’s instructions
(Applied Biosystems).
Antibodies and reagents. Anti-WIP1 antibody (A300-664A, 1:500), anti-DDX1
(A300-521A, 1:2000), anti-Drosha (A301-886A, 1:2000) and anti-DDX5 (A300-
523A, 1:2000) were purchased from Bethyl Laboratories. Anti-HER2 antibody
(18299-1-AP, 1:2000) was purchased from Proteintech. Anti-p21 (sc-397, 1:1000),
anti-WIP1 (sc-376257, 1:500), anti-GAPDH (sc-20357, 1:5000), anti-Actin (sc-
1616, 1:5000), HRP-anti-goat IgG (#2020, 1:5000), HRP-anti-rabbit IgG (#2054,
1:5000) and HRP-anti-mouse IgG (#2055, 1:5000) antibodies were purchased from
Santa Cruz. Anti-AKT (#4691, 1:2000), anti-phospho-AKT (S473, #9018, 1:2000),
anti-Chk2 (#2662 S, 1:2000), anti-phospho-Chk2 (#2661 S, 1:2000), anti-Ki-67
(#9449, 1:500) and anti-cleaved caspase3 (#9661 S, 1:200) were purchased from Cell
Signaling. Trastuzumab (Herceptin, Genentech) and GSK-2830371 (Active Bio-
chem) were used to target HER2 and WIP1 in vitro and in vivo. Antisense miR-21
miRZip (System Bioscience) expressing constructs were used to inhibit mature
miR-21 function in vitro and in vivo (Dox-induced stable knockdown as shown in
Fig. 6). To evaluate and measure mature miR-21 activity in the cells, pmirGLO
Dual Luciferase miR-21 vector was used in vitro. mirVana miR-21 inhibitor
(Ambion, Life Technology) was used for in vivo miR-21 inhibition with nano-
particles. PLGA (lactide: glycolide= 75: 25, MW: 4,000-15,000), PF127, and
organic solvents were purchased from Sigma (St. Louis, MO, USA). Agarose,
ethidium bromide and loading buffer were purchased from Thermo Fisher Sci-
entiﬁc (Grand Island, NY, USA). DPPC was purchased Anatrace (Maumee, OH,
USA). Chitosan oligosaccharide of pharmaceutical grade (MW: 1.2 KDa, 95%
deacetylation) was purchased from Zhejiang Golden Schell Biochemical Co. Ltd
(Zhejiang, China). Methyl aminomethanimidothioate hydroiodide was purchased
from Santa Cruz Biotechnology (Dallas, TX, USA).
Generation of doxycycline-inducible knocked-down cell lines. Lentiviral pGIPZ
vector expressing non-speciﬁc silencing shRNA control, WIP1 and DDX5 shRNAs
were obtained from the MD Anderson shRNA and ORFome Core Facility (ori-
ginally from Open Biosystems) and sub-cloned to pTRIPZ vector according to the
manufacturer’s instructions. To generate Dox-inducible anti-sense miR-21 miRZip
expressing cell lines, anti-miR21 expression cassette was sub-cloned to pLKO-Tet-
On vector. Cells were infected with lentiviruses in the presence of polybrene (8 μg
ml−1). To establish stable knockdown cell line, lentiviral shRNA-transduced cells
were selected with puromycin (2 μg ml−1) 48 h post-infection and individual
colonies were propagated and validated for expression by Western blotting (pro-
tein) and qRT-PCR (mRNA).
Genomic DNA isolation and copy number validation. Total genomic DNA was
extracted from human cell lines using DNeasy Blood & Tissue Kit (Qiagen)
according to the manufacturer’s puriﬁcation instructions. The copy number vali-
dation for HER2, WIP1, and MIR21 were determined by quantitative PCR assays
using iTaq Universal SYBR Green Supermix (Bio-Rad) on an Applied Biosystems
7900HT Sequence Detection System.
Immunoblotting. Immunoblotting was performed as described previously54.
Brieﬂy, total cell lysates were solubilized in lysis buffer (50 mM Tris, pH 7.5, 150
mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Triton X-100, 1 mM phe-
nylmethylsulfonyl ﬂuoride, 1 mM sodium ﬂuoride, 5 mM sodium vanadate, 1 μg
each of aprotinin, leupeptin, and pepstatin per ml). Proteins were resolved by SDS-
PAGE gels and then proteins were transferred to PVDF membranes (Bio-Rad). The
membranes were blocked with 5% nonfat milk for 1 h at room temperature prior to
incubation with indicated primary antibodies. Subsequently membranes were
washed and incubated for 1 h at room temperature with peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology). Following several washes, che-
miluminescent images of immunodetected bands on the membranes were recorded
on X-ray ﬁlms using the enhanced chemiluminescence (ECL) system (Perkinelmer)
according to the manufacturer’s instructions. Uncropped scans of the western blots
are presented in the Supplementary Fig. 9.
Cell viability assay. Equal numbers of cells were plated in 12 well plates in
triplicate. After incubation with indicated reagents for 3–5 days, cell viability was
quantiﬁed using Vi-Cell cell viability analyzer (Beckman Coulter).
Soft agar colony formation assay. Two thousand cells per well mixed in a 0.35%
agarose/complete media suspension were seeded onto 0.7% agarose/complete
media bottom layer in 12-well plates. Cells grew at 37 °C for 3 weeks until the
colonies were visible to the naked eye. Colonies were then stained with p-iodoni-
trotetrazolium violet (1 mgml−1, Sigma) overnight and then photographed. The
colonies were counted by Image J software, and the data were plotted. Each
experiment was performed in triplicate.
Mammosphere culture. Mammary tumor cells were plated onto ultralow
attachment plates (Corning) at a density of 20,000 viable cells ml−1 (to obtain
primary mammospheres) in a serum-free DMEM-F12 (Invitrogen) supplemented
with 5 μg ml−1 insulin, 20 ng ml−1 epidermal growth factor and 20 ng ml−1 basic
ﬁbroblast growth factor (Sigma), and 0.4% bovine serum albumin (Sigma). After
10 days, number and size of mammospheres were estimated.
Immunoprecipitation. Cells were lysed on ice for 30 min in IP buffer (1% NP-40,
50 mM Tris-HCl, 500 mM NaCl, 5 mM EDTA) containing protease inhibitor
cocktail. Cell lysates (700 μg) were incubated overnight with 3 µg of antibodies or
normal IgG at 4 °C with rotary agitation. Protein A-sepharose beads were added to
the lysates and incubated for additional 4 h. Beads will be washed three times with
IP buffer and boiled for 10 min in 3% SDS sample buffer. Total cell lysates and
immunoprecipitates were separated by SDS-PAGE and analyzed by Western
blotting.
RNA immunoprecipitation (RIP) assay. Cell were crosslinked for 20 min with 1%
formaldehyde, and cell pellets were resuspended in buffer B (1% SDS, 10 mM
EDTA, 50 mM Tris–HCl (pH 8.1), 1×protease inhibitor, 50 U ml−1 RNase inhi-
bitor). Incubated 10 min in ice, the pellets were disrupted by sonication, and the
lysates were subjected to immunoprecipitation with control IgG or anti-DDX1 or
anti-Drosha antibody, followed by stringent washing, elution, and reversal of
crosslinking. The RNA was resuspended in 20 μl of TE buffer (10 mM Tris–HCl,
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pH 7.5, 1 mM EDTA, 50 U ml−1 RNase inhibitor) and incubated with DNase I for
30 min at 37 °C to remove any remaining DNA. After extraction with phenol:
chloroform:isoamyl alcohol (25:24:1), RNA was precipitated with ethanol and
dissolved in 20 μl of DEPC-treated water. RNA (5 μl) was used for the cDNA
synthesis reaction. Quantitative PCRs were then performed on real-time PCR
machine.
RNA isolation, qRT–PCR, and miRNA PCR array. Total RNA was isolated using
TRIzol reagent (Life Technologies) and then reverse-transcribed using iScript
cDNA Synthesis Kit (Bio-Rad). The resulting cDNA was used for qPCR using iTaq
Universal SYBR Green Supermix (Bio-Rad) with gene-speciﬁc primers and these
results were normalized to β-actin control. To analyze miRNAs, total RNA was
isolated using Trizol reagent according to the manufacturer’s instructions (Life
Technologies) and was then reverse transcribed with a Universal cDNA Synthesis
Kit II (Exiqon). cDNA was used for qPCR using SYBR Green master mix (Exiqon)
on ABI 7900 real-time PCR cycler. miRNA LNA PCR primer sets (Exiqon) and
gene speciﬁc primers were used for detecting miRNA and mRNA levels and data
was normalized to internal control, U6 (miRNA) or GAPDH (mRNA). RT-PCR
primers are shown in Supplementary Table 1. For deep sequencing, primary mouse
mammary epithelial cells (8 weeks old) were isolated as previously reported55,56
and then total mRNA was extracted using Direct-zol RNA extraction kit (Zymo
Research) and then submitted for deep sequencing. Both raw and processed data
have been deposited in the GEO database (Accession Number GSE119210).
miR-21 in situ hybridization. Breast cancer tissue array (BR10010) was purchased
from Biomax.us, containing 50 cases of breast carcinoma. As described pre-
viously57, the tissue slides were ﬁrst digested with 15 μg ml−1 proteinase K for 10
min at room temperature, and then hybridized with the double-DIG-labeled
mercury LNA microRNA probe (Exiqon) for 2 h at 50 °C on Ventana Discovery
Ultra (Ventana Medical Systems). The digoxigenins were then detected with a
polyclonal anti-DIG antibody and alkaline phosphatase-conjugated second anti-
body using NBT-BCIP as the substrate. Raw images were captured with the same
exposure and gain settings from all slides and saved as TIF ﬁles, and were analyzed
using intensity measurement tools of Image-Pro Plus software.
Synthesis of nanoparticles. The nanoparticles were synthesized using a double
emulsion method with a slight modiﬁcation58. First, Chitosan was modiﬁed with
guanidine group according to the literature59 to form chitosan-guanidine (CG). To
capture carbon dioxide (CO2), CG aqueous solution was bubbled with CO2 for 1 h
to form CG-CO2. PLGA (20mg) and DPPC (10 mg) were dissolved in 2 ml
dichloromethane (DCM) and 50 µl GSK2830371 in tetrahydrofuran (THF)
solution (40 mgml−1) was then added, the above mixture together with 400 µl
of DI water containing 500 µg ml−1 anti-miR21 oligonucleotide and 500 µg ml−1
CG-CO2 were transferred into a 50 ml centrifuge tube. Then the immiscible
solutions were emulsiﬁed by sonication for 1 min using a Bransan 450 soniﬁer.
Next, this ﬁrst emulsion and 8 ml of chitosan-PF127 solution (in DI water) were
emulsiﬁed by sonication for 1 min. After rotary evaporation to remove the organic
solvent, the nanoparticles were collected by centrifugation at 10,000×g for 10 min
at room temperature and washed twice with DI water.
Characterization of nanoparticles. The nanoparticle was characterized using both
transmission electron microscopy (TEM) and dynamic light scattering (DLS). First,
nanoparticles were soaking in soaking in Phosphate Buffer (pH 7.4, pH 6.0) or
Acetate Buffer (pH 5.0), respectively, for 6 h. For TEM study, the nanoparticles
were negatively stained with uranyl acetate solution (2%, w/w) and examined using
an FEI (Moorestown, NJ, USA) Tecnai G2 Spirit transmission electron microscope.
The nanoparticle size was determined using a Brookhaven (Holtsville, NY, USA)
90 Plus/BI-MAS dynamic light scattering instrument.
Electrophoretic gel assay. Free anti-miR-21 oligonucleotide and in-MW@NP
(in PBS or serum) were mixed with loading buffer, and then loaded into 2% agarose
gel with 0.5 μg ml−1 ethidium bromide. Electrophoresis was conducted in 1× TEA
buffer at 80 V for 10 min. The result gels were analyzed using a UV illuminator
(FluorChemTM E System, CA, USA) to show its location of anti-miR21
oligonucleotide.
Cell uptake and intracellular distribution of nanoparticles. Dex-Rho was
encapsulated inside the nanoparticles using the same method described above. To
study cellular uptake and subcellular localization of nanoparticles, HER8R cells
were treated with Dex-Rho@NP or free Dex-Rho for 1–6 h at 37 °C. The cells were
further treated with medium containing 90 nM LysoTracker Green and 50 nm
DAPI. Then, the cells were further examination using an Olympus FluoViewTM
FV1000 confocal microscope.
Mouse lines. The MMTV-ErbB2 transgenic mice60 and miR-21 knockout mice28
were obtained from The Jackson Laboratory, Bar Harbor, ME. Details of the WIP1
deﬁcient mice have been previously described61. Mice were interbred and main-
tained on FVB/C57BL6 hybrid background in pathogen-free conditions at M.D.
Anderson Cancer Center and used in accordance with Institutional Animal Care
and Use Committee-approved protocols. Virgin MMTV-ErbB2 and bitransgenic
MMTV-ErbB2; MIR21−/− and MMTV-ErbB2; WIP1−/− female mice were pal-
pated weekly to detect the presence of mammary tumors starting at 90 days of age.
When tumor reachs 10 mm in diameter, tumor and normal, non-tumourigenic
mammary tissue was harvested from the same animal at the time of tumor harvest.
Breast tumor xenograft mouse model. Female NOD/SCID mice (6–8 weeks old)
were purchased from Jackson Laboratories. All studies were approved and
supervised by the Institutional Animal Care and Use Committee at the MD
Anderson Cancer Center and Indiana University School of Medicine. For the
breast cancr orthotopic xenograft model, nude mice were injected with 5 × 106
HER18 (mixed with matrigel in 100 µl PBS) human breast cancer cells in the
mammary fat pad as discribed previously62,63. The nude mice were supplementary
with weekly subcutaneous estradiol cypionate injections (3 mg kg−1 per week),
starting 1 week prior to injection of tumor cells. After initial establishment of
tumor (50 mm3), mice were randomly grouped and treated with or without 1 µg ml
−1 Dox in drinking water for 4 weeks. The Dox water was changed every other day.
The adminstration of trastuzumab (5 mg kg−1) was performed biweekly for 4
consecutive weeks by intravenous injection.
For xenograft tumor studies using nanoparticles, mice bearing trastuzumab-
resistant HER18 or BT-474 tumors were randomized to four groups and received
the following treatments: (1) control nanoparticles; (2) WIP1 inhibitor
nanoparticles (5 mg kg−1); (3) miR-21 inhibitor nanoparticles (1 mg kg−1); and
(4) WIP1 inhibitor+miR-21 inhibitor nanoparticles. Nanoparticles were
administered twice weekly by intravenous injection, and tumor size and body
weight changes were monitored biweekly. Tumor size was measured using a
caliper, and tumor volume was calculated using the standard formula: 0.5 × L ×W2,
where L is the longest diameter and W is the shortest diameter. For the tumor
metastasis model, female NOD/SCID mice were injected with trastuzumab-
resistant HER18-luc cells via tail vein injection. Lung metastasis was monitored
by the IVIS bioluminescent imaging sysem. Mice were euthanized when they met
the institutional euthanasia criteria for tumor size and overall health condition.
Tumors were removed, photographed and weighed. The freshly dissected tumor
tissues were ﬁxed in 10% buffered formalin overnight, transferred to 70% ethanol,
embedded in parafﬁn, sectioned and stained with hematoxylin and eosin and
indicated antibodies.
Immunohistochemistry. The tumors were ﬁxed in 10% neutral buffered
formalin and embedded in parafﬁn and 5-µm tissue sections were serially cut
and mounted on slides. The sections were de-parafﬁnized in xylene, re-hydrated,
and boiled for 10 min in antigen retrieval buffer. After retrieval, the sections
were washed with distilled water and endogenous peroxidase activity was blocked
using 3% H2O2 in TBS for 15 min and then blocked with blocking solution
(1% bovine serum albumin, 10% normal serum in 1× TBS). Samples were
incubated with primary antibodies overnight at 4 °C, washed three times with
TBST buffer, and then incubated with biotinylated goat anti-rabbit or anti-mouse
IgG (GR608H, BioCare Medical). A streptavidin–biotin peroxidase detection
system with 3, 3′-diaminobenzidine as substrate was used according to the
manufacturer’s instructions (DAB Peroxidase Substrate Kit, Vector Laboratory).
Sections were counterstained with haematoxylin. For immunocytochemistry,
cells on chamber slide were ﬁxed in 3.7% paraformaldehyde for 10 min, and
permeabilzed by 0.2% Triton X-100 for 5 min and then blocked with blocking
solution. After incubation with primary antibodies, cells were washed with PBS
three times and incubated with Alexa ﬂuor 488 or 594 conjugated antibodies
(Life Technologies) and counter stained with Hoechst 33258. After mounting,
signals were observed under microscope. Breast cancer tissue array (BR10010)
was purchased from Biomax.us.
Statistical analysis. Each experiment was repeated three times or more. Unless
otherwise noted, data are presented as mean ± SD, and Student’s t-test (unpaired,
two-tailed) was used to compare two groups of independent samples, whereas one-
way ANOVA followed by Tukey’s t-test was conducted to compare three or more
groups of independent samples. Survival analysis was done using the Kaplan–Meier
method, as assessed using a log-rank Mantel-Cox test. p < 0.05 was considered
statistically signiﬁcant.
Data availability
The RNA-sequencing data have been deposited in the GEO database [https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE119210]. All other relevant data are available
from authors upon request.
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